Literature DB >> 1310471

Expression of SPARC is correlated with altered morphologies in transfected F9 embryonal carcinoma cells.

E A Everitt1, E H Sage.   

Abstract

SPARC (secreted protein, acidic and rich in cysteine) is a Ca(2+)-binding glycoprotein that has recently been identified as a member of a group of proteins that exert antispreading effects on various cultured cells. In addition, SPARC is induced during the later stages of F9 stem cell differentiation to parietal endoderm (PE). When treated with retinoic acid and dibutyryl cAMP, F9 cells differentiate into PE and SPARC mRNA is increased approximately 20-fold. To determine whether the chronic overexpression or inhibition of expression of SPARC would affect the morphology, attachment, or differentiation of F9 cells, we transfected undifferentiated F9 cells with cDNA encoding SPARC or anti-sense SPARC and cloned lines that expressed either elevated or reduced levels of SPARC protein. The transfected F9 cells displayed altered morphologies in culture: cells of four overexpressing lines appeared clumped and rounded, whereas those of three underexpressing lines were spread and flat, in comparison to controls. Moreover, the morphological differences persisted during differentiation of the lines to PE. The altered morphology was not due to an increased expression of collagenases and did not affect the ability of the cells to attach and adhere to tissue culture plastic. The altered phenotype of the transfected F9 cells appeared to be directly related to the level of extracellular SPARC. Since overexpression of SPARC induced rounding and aggregation of F9 cells in culture, we propose that SPARC facilitates modulation of cell-cell or cell-substrate interactions in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310471     DOI: 10.1016/0014-4827(92)90471-j

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer.

Authors:  Stephanie Thomas; Peter Waterman; Suelin Chen; Brett Marinelli; Marc Seaman; Scott Rodig; Robert W Ross; Lee Josephson; Ralph Weissleder; Kimberly A Kelly
Journal:  J Nanomed Nanotechnol       Date:  2011-08

2.  Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts.

Authors:  S Blazejewski; B Le Bail; L Boussarie; J F Blanc; L Malaval; K Okubo; J Saric; P Bioulac-Sage; J Rosenbaum
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

Review 3.  Anti-cancer role of SPARC, an inhibitor of adipogenesis.

Authors:  Ganji Purna Chandra Nagaraju; Dipali Sharma
Journal:  Cancer Treat Rev       Date:  2011-01-14       Impact factor: 12.111

4.  Indomethacin and retinoic acid modify mouse intestinal inflammation and fibrosis: a role for SPARC.

Authors:  Borut Klopcic; Amber Appelbee; Warren Raye; Frances Lloyd; James C I Jooste; Cynthia Heather Forrest; Ian Craig Lawrance
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

5.  The Caenorhabditis elegans homologue of the extracellular calcium binding protein SPARC/osteonectin affects nematode body morphology and mobility.

Authors:  J E Schwarzbauer; C S Spencer
Journal:  Mol Biol Cell       Date:  1993-09       Impact factor: 4.138

6.  Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.

Authors:  M Riminucci; L W Fisher; A Shenker; A M Spiegel; P Bianco; P Gehron Robey
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

Review 7.  Signaling pathways in breast cancer metastasis - novel insights from functional genomics.

Authors:  Mario Andres Blanco; Yibin Kang
Journal:  Breast Cancer Res       Date:  2011-03-14       Impact factor: 6.466

8.  Aberrant methylation of SPARC in human lung cancers.

Authors:  M Suzuki; C Hao; T Takahashi; H Shigematsu; N Shivapurkar; U G Sathyanarayana; T Iizasa; T Fujisawa; K Hiroshima; A F Gazdar
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.